Please select the option that best describes you:
Do you offer maintenance rituximab in transplant ineligible patients with mantle cell lymphoma?
Are there any subsets of patients that you're more inclined to offer maintenance?
Answer from: Medical Oncologist at Academic Institution
The data on the role of rituximab maintenance therapy in transplant ineligible patients with mantle cell lymphoma are not straightforward to interpret. The most often cited experience (Kluin-Nelemans, et al., PMID 22873532) is a complicated study with two randomizations: induction therapy was either...
Sign in or Register to read more